In response to tariff policies under former U.S. President Donald Trump, Taiwan’s biomedical companies have in recent years actively expanded into the U.S. to strengthen “Made in America” capabilities. By establishing or expanding manufacturing facilities stateside, these companies aim to enhance their competitiveness in the world’s largest pharmaceutical market.

Following Bora Pharmaceuticals’ major acquisitions last year to scale up its U.S. manufacturing capacity, leading pharmaceutical firms such as YungShin and Standard Chem & Pharm have also moved to expand their production lines in the U.S. Meanwhile, Medeon Biodesign, an innovative medical device company, which had previously followed a “U.S. orders, Taiwan manufacturing” model, is now considering reinforcing its U.S. production footprint.

In 2024, Bora Pharmaceuticals completed several significant acquisitions: Upsher-Smith Laboratories, the largest pharmaceutical company in Minnesota; a sterile injectable manufacturing facility from Emergent BioSolutions; and Pyros, a rare disease drug developer based in New Jersey. Bora also invested in Tanvex BioPharma, thereby incorporating its U.S. operations into its biologics production base.

YungShin Global Holding Corporation recently reported that its California subsidiary, Carlsbad Technology, which previously produced 800 million to 1 billion doses annually, has completed product optimization initiatives that are expected to increase output by 30%. Starting in the second quarter of this year, Carlsbad Technology began expanding its production lines, with plans to construct a new facility in the third quarter. This expansion is projected to double YungShin’s U.S. production capacity within two years.

Standard Chem & Pharm’s affiliate Everest, in which it holds a 5.45% stake, specializes in generic drugs and novel formulations. Following its acquisition of U.S.-based Magnifica, Everest gained access to the TULEX manufacturing site in New Jersey. The company now possesses two key platforms: controlled-release formulation and micronization technology, attracting interest from various pharmaceutical companies for collaborative development.

Medeon Biodesign stated that its original CDMO strategy was centered on “receiving orders in the U.S., manufacturing in Taiwan,” but it does not rule out the possibility of strengthening its production capabilities within the U.S. as part of future expansion efforts.

Resource: 川普關稅政策下 生醫族群積極東進